Thursday, August 15, 2019 – Today
, a biotechnology company developing the end-to-end drug discovery pipeline utilizing next generation artificial intelligence, and the
University of Copenhagen
, announce the presentation of Anastasia Georgievskaya, CEO of Haut.AI, at the
6th Aging Research, Drug Discovery, and AI Forum
during the Basel Life Congress, September 10-12, 2019 in Basel, Switzerland.
Ageing processes follow different patterns for each skin type. The talk presents the research on how face and hand skin features depend on the age of people with a distinct phenotype. We created two computer vision algorithms for predicting age on face and hand images, both based on fully-convolutional neural networks. Our research can help measure the complex effects of anti-ageing products or any dermatological procedures after treating ageing hands objectively.
“Our research on non-invasive ageing biomarkers will help measure the complex effects of anti-ageing products and therapies after treating skin condition objectively. I am so thrilled to represent Haut.AI at the 6th Annual Ageing Drug Discovery and AI Forum, and share some of our insights, experiences, and the lessons we’ve learned over the last couple of years. We encourage everyone within the industry to register for this event and engage in collective conversations with your peers and industry specialists,” said Anastasia Georgievskaya, CEO of Haut.AI.
“I am extremely excited that Anastasia Georgievskaya, CEO of Haut.AI, will join our meeting in Basel. Anastasia Georgievskaya and team recently created one of the most accurate AI based age-predicting algorithms out there, a critical step towards interventions targeting the aging process. I am therefore over the moon that Anastasia Georgievskaya is joining us,” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“Over the last 5 years, the “Ageing & Drug Discovery” and “AI for Healthcare” forums have been leading events at Basel Life, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled “the 6th Ageing, AI and Drug Discovery Forum” to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet,” said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019.
“The 6th annual Ageing Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in ageing and longevity research covering the theory, applications and convergence of these three exciting areas,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 6th Ageing Research, Drug Discovery, and AI Forum Basel will bring together leaders in the ageing, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of ageing and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: ageing. The Forum will be held in Basel, Switzerland, September 10-12, 2019.
For further information, images or interviews, please contact:
About Anastasia Georgievskaya
Anastasia Georgievskaya is the Co-founder and CEO of Haut.AI, an IT company developing AI-powered computer vision algorithms for skincare and skin health applications. The big goal of Haut.AI is to help people achieve the best skin look by using imaging data, to allow non-specialists in AI to introduce it to daily operations, and in general, help their clients experience healthy aging. Anastasia has 3 years’ experience of integrating AI and computer vision algorithms into consumer companies’ technology stacks. She has two degrees in bioengineering and biophysics.
Haut.AI is an Estonian startup developing AI algorithms for recognition of skin pathologies. The developments are based on the algorithms of computer vision and machine learning including deep learning. The company’s core product is SaaS for skincare. The main goal is to help clients build new skincare strategies, transform and digitalize interaction between business and customer, and facilitate R&D.
About Insilico Medicine
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and ageing research.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the
global top 100 AI companies by CB Insights
. In 2018 it received the
Frost & Sullivan 2018 North American Artificial Intelligence for Ageing Research and Drug Development Award
accompanied with the industry brief. Brief company video:
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer’s, Parkinson’s and cardiovascular diseases. Although the cause of ageing is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of ageing in model organisms. These findings suggest that normal ageing and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University – to quote the University Statute – is to ‘conduct research and provide further education to the highest academic level’. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.
About Basel Life 2019
In this symposium, leaders in the ageing, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of ageing and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: ageing. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet.
Conference Official Website: